TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00457821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor 25 mg/75 mg
Description: 25 mg or 75 mg q12h for a total of 28 days (Part 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor 75 mg/150 mg
Description: 75 mg or 150 mg q12h for a total of 28 days (Part 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor 150 mg or 250 mg
Description: 150 mg or 250 mg of ivacaftor q12h for 28 days (Part 2)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given q12h for 28 days each in Part 1 and Part 2 of the study
Study: NCT01666535

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Influenza vaccination

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Influenza vaccination
Study: NCT02298179

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV F subunit 45 μg No adjuvant
Description: 2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV F subunit 45 μg Aluminum hydroxide adjuvant
Description: 2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV F subunit 45 μg MF59 adjuvant
Description: 2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV F subunit 90 μg No adjuvant
Description: 2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV F subunit 90 μg Aluminum hydroxide adjuvant
Description: 2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
Study: NCT02851134

Intervention type: BIOLOGICAL
Intervention: blood and stools samples
Description: biological collection
Study: NCT02298179

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV F subunit 90 μg MF59 adjuvant
Description: 2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
Study: NCT01506427

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [F-18] HX4
Description: A single dose of 10 mCi, injected intravenously.
Study: NCT00706407

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fully integrated Uro-NIRS:UDS
Description: As part of standard care subjects will be undergoing a standard bladder pressure diagnostic procedure. This standard procedure will involve the insertion of a catheter (a plastic tube) into the urethra and the measurement of pressure within the bladder. For subjects taking part in this study, the health of the bladder will measured by using light instead of pressure. A patch, the size of cell phone or deck of playing cards, will be taped to the skin in the middle of the abdomen, above the bladder. Using laser light that is 300 billion times weaker than the light from a regular household 100-Watt light bulb, the Laborie and Urodynamix device will take measurements through the skin without inserting anything into the body.
Study: NCT00003623

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: multivitamin
Study: NCT02298179

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV F subunit 135 μg No adjuvant
Description: 2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV F subunit 135 μg Aluminum hydroxide adjuvant
Description: 2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV F subunit 135 μg MF59 adjuvant
Description: 2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
Study: NCT01261728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Cisplatin
Description: Patients will receive four cycles of GC administered every 21 days. Gemcitabine 1,000 mg/m2 and Cisplatin 35 mg/m2 will be administered intravenously on days 1 and 8. A total of four cycles of therapy will be administered at 21 day intervals followed by radical nephroureterectomy or distal ureterectomy.
Study: NCT03537742

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alirocumab
Description: alirocumab 150mg Subcutaneous

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo to match alirocumab
Study: NCT00087022

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: girentuximab
Description: Given IV

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given IV
Study: NCT04580433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-Restricted Feeding
Description: The trial consists of a 1-week baseline weight stabilization period followed by a 5-week TRF intervention period.~Participants will be instructed to eat freely from 8 a.m. to 4 p.m. daily and fast from 4 p.m. to 8 a.m. the next day.
Study: NCT02195232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoquercetin
Study: NCT04611425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Patients will receive an infusion of Remimazolam for a maximum duration of 48 hours. The dose of Remimazolam will be adapted according to the ICU units protocol of analgesia-sedation management, based on validated scale (Richmond Assessment Sedation Scale). Owing to previous data gathered through a previous study in Japan, the initial dose of infusion will be within a 0.2-0.5 mg/min range. The dose of Remimazolam can be increased or decreased by 0.1mg/min when needed. The maximum dose of Remimazolam will be set at 1 mg/min.
Study: NCT00801489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim-sndz
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03128021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levomilnacipran Pill
Description: Double-blinded, randomly assigned
Study: NCT01013558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: 0.15 microgram/kg/min continuous infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: continuous infusion
Study: NCT04245839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JCAR017
Description: JCAR017
Study: NCT03832855

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pING-hHER3FL
Description: Plasmid vaccine containing HER3
Study: NCT03648489

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Please refer to arm/group description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Please refer to arm/group description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK228
Description: Please refer to arm/group description
Study: NCT04177771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Adjustable lens (LAL) and Light Delivery Device (LDD) - Pre-COVID Population
Description: Experimental treatment group will receive Light adjustable lens with Light delivery Device treatments

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SofPort LI61AO IOL
Description: Control treatment group will receive SofPort LI61AO IOL

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tecnis ZCB00 or ZTC150 IOL
Description: Control treatment group will receive Tecnis ZCB00 or ZTC150 IOL
Study: NCT00003623

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01025323

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification
Description: DASH diet and exercise advice
Study: NCT06759246

Intervention type: PROCEDURE
Group type: OTHER
Intervention: implant placement
Description: Placement of short implants for the rehabilitation of single-tooth edentulism in atrophic maxillae near the maxillary sinus.
Study: NCT01025323

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification
Description: DASH diet, exercise with systematic instruction by a dietician and/or coordinator
Study: NCT02730624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Description: 4.5 g of piperacillin/tazobactam in 100 ml of normal saline solution was administered via an infusion pump at a constant flow rate 30 min every 6 h and blood sample were obtained by direct venepuncture at 0, 0-0.5, 0.5-2, 2-4 and 4-6 hour after drug administration
Study: NCT02937493

Intervention type: BEHAVIORAL
Intervention: Lunar phases
Description: Observation if lunar phases had an influence on occurrence of IPV

Intervention type: BEHAVIORAL
Intervention: Lunar phases
Description: Observation if lunar phases had an influence on occurrence of IPV
Study: NCT02520219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GDP
Description: GDP is a a combination therapy,repeated every 21 days. GEM(gemcitabine)1000mg/m2,ivgtt,30,d1、8; DXM(dexamethasone),40mg/d,p.o,d1-4; DDP(cis-platinum),75mg/m2,ivgtt,\>1h,d1; or DDP25 mg/m2,ivgtt,\>1h,d1-3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDP
Description: GDP is a a combination therapy,repeated every 21 days. GEM(gemcitabine)1000mg/m2,ivgtt,30,d1、8; DXM(dexamethasone),40mg/d,p.o,d1-4; DDP(cis-platinum),75mg/m2,ivgtt,\>1h,d1; or DDP25 mg/m2,ivgtt,\>1h,d1-3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endostar
Description: Endostar is a continuous intravenous injection pump, continuous intravenous pumped by seven consecutive days,d1- d7, which is 168 hours .Endostar pumping well dose is 30 mg every 24 hours.~Repeated every 21 days.
Study: NCT01023542

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: delayed, low-dose CNI
Description: immunosuppression
Study: NCT04080297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral capsule of Q-122
Study: NCT01023542

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BU-CNI
Description: Immunosuppression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BU-Everolimus
Description: Immunosuppression
Study: NCT04690075

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition Management and Dietary Fiber
Description: Routine nutrition management and dietary fiber supplements based on recommendation for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition Management
Description: Routine nutrition management for 12 weeks.
Study: NCT06762418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RMR+SME
Description: Patients will be asked to wear this removable appliance for 16 hours per day. The exapnsion screw is activated twice a week.
Study: NCT03567616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet; oral
Study: NCT06762418

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BAIMT+RME
Description: The elastics is worn 18 hours per day to achieve the sagittal correction. The RME appliance on the upper jaw is activated twice daily until achieving the required expansion.
Study: NCT03142399

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: whey protein
Description: Supplementation with whey protein isolate or maltodextrin (30 grams per day) for 12 weeks associated with supervised exercise and nutritional counseling in patients with heart failure.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey protein
Description: Supplementation with whey protein isolate or maltodextrin (30 grams per day) for 12 weeks associated with supervised exercise and nutritional counseling in patients with heart failure.
Study: NCT01644695

Intervention type: PROCEDURE
Intervention: Bony Anchoring Reinforcement System
Description: Abdominal exposure was obtained via a lower horizontal incision, a vertical incision, or through a combination horizontal/vertical (ie fleur-di-lis) pattern. Exploratory laparotomy, lysis of intra-abdominal adhesions with hernia sac excision was performed prior to fascial closure. Primary closure of the abdominal fascia was performed with a combination of components separation and placement of biologic mesh over the fascial incision line in onlay fashion. Typically three bone anchors were used to secure the synthetic mesh at the pubic symphysis and two bone anchors to the ASIS bilaterally. The superior aspect of the marlex mesh was sutured to fascia avoiding any incorporation of the costal perichondrium. Quilting sutures were used to secure the mesh to the rest of the abdominal fascia.
Study: NCT01426919

Intervention type: OTHER
Intervention: Head CT scan and blood draw within 12 hours of injury
Study: NCT01989780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprorelin
Study: NCT05838053

Intervention type: PROCEDURE
Intervention: Lobectomy with systemic lymph node dissection
Description: Lobectomy with hilar and mediastinal lymph node dissection is performed. Segmentectomy with hilar and mediastinal lymph node dissection is performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.

Intervention type: PROCEDURE
Intervention: Segmentectomy with systemic lymph node dissection
Description: Segmentectomy with hilar and mediastinal lymph node dissection is performed. If the tumor located at inter-segment plane and without sufficient resection margin distance, a combined segmentectomy will be performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
Study: NCT01388439

Intervention type: DRUG
Intervention: Oseltamivir
Description: Treatment dose was oseltamivir 3 mg/kg/dose by mouth (PO) twice daily. Prophylactic dose was oseltamivir 1 mg/kg/dose PO once daily to infants \< 28 weeks postmenstrual age (PMA), 1 mg/kg/dose PO twice daily to infants 28 - 38 weeks PMA, and 3 mg/kg/dose PO once daily to infants \> 38 weeks PMA. Dosing in infants \< 28 weeks PMA was chosen based on unpublished data from Acosta et al. This data was obtained from phone contact with Dr. Peter Gal, co-author of the study. Dosing in infants 28 - 38 weeks PMA was chosen based on published data from Acosta et al.1 Dosing in infants \> 38 weeks PMA and less than 3 months postnatal age was chosen based on data from Kimberlin et al. Dosing in infants \> 38 weeks PMA and greater than 3 months postnatal age was per the recommendations of the Advisory Committee on Immunization Practices of the United States Department of Health and Human Services.
Study: NCT04265508

Intervention type: OTHER
Intervention: Assessment of hemostatic profile
Description: To assess the hemostatic profile, platelet function was analyzed by multiple electrode aggregometry (MEA) using Multiplate (ADP-, ASPI- and TRAP-test) and thrombelastometry using ROTEM (EXTEM, INTEM, FIBTEM)

Intervention type: OTHER
Intervention: Assessment of hemostatic profile
Description: To assess the hemostatic profile, platelet function was analyzed by multiple electrode aggregometry (MEA) using Multiplate (ADP-, ASPI- and TRAP-test) and thrombelastometry using ROTEM (EXTEM, INTEM, FIBTEM)
Study: NCT04213703

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for this study
Study: NCT01524003

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: cryotherapy treatment of the uterine cervix

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colposcopy
Description: Colposcopy, biopsy and LEEP based on the pathology results
Study: NCT04720040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mind STIM
Description: transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
Study: NCT02524015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel physical therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Standard physical therapy
Study: NCT00218582

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Double Trouble in Recovery
Description: Dual focus 12 step mutual aid groups for persons with co-occurring disorders (psychiatric and substance use disorders), provided within the context of standard psychiatric day treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard psychiatric day treatment
Description: Individual counseling, groups, medication
Study: NCT01094314

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: embryo culture medium
Description: comparison between two types of embryo culture medium

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: embryo culture medium
Description: comparison between two types of embryo culture medium
Study: NCT05734053

Intervention type: OTHER
Intervention: Nilotinib
Description: There was no treatment allocation. Patients administered Nilotinib by prescription could be enrolled.
Study: NCT01122342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone propionate
Description: Testosterone USP micronized powder at a dose of 1mg/gr will be made into a paste with polysorbate 80 NF liquid and will be placed in an emollient cream base. A calibrated applicator will be supplied to measure out doses containing 300mcg of testosterone for daily application. The cream will be applied daily for 28 days. As above if safety and efficacy endpoints are met at this dose a lower dose (150mcg) will be used and if in tun this meets safety and efficacy endpoints a lower dose (75mcg) will be used.
Study: NCT04396769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FLOW-PA
Description: Classes were designed to provide the opportunity to be physically activity at a moderate-vigorous level. Each station included exercise options to accommodate varying fitness levels and offer students choice. Heart rate monitors provided consistent biofeedback to students throughout the intervention. Participants were evaluated based on the number of minutes they spent each class between 60-80% of their maximal heart rate. Games were intermixed either as a station or as a break in the circuit (e.g. short game of tag half-way through the workout) to make physical activity enjoyable and engaging.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PE class as usual
Description: PE teachers were instructed to teach class as usual. Research staff were not involved in class activities or instruction. In this school district PE class as usual includes sports-based instruction in which students learn the rules to games and then practice playing.
Study: NCT02196116

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PET
Description: PET Scan with \[18F\]-Flutemetamol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET
Description: PET Scan with \[18F\]-Flutemetamol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET
Description: PET Scan with \[18F\]-Flutemetamol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neuropsychological tests

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuropsychological tests

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuropsychological tests
Study: NCT03342573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cosentyx
Description: Cosentyx 300 mg SQ week 0-4, then every q4 weeks for a total of 28 weeks.
Study: NCT02802241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: peppermint oil